MedTrace Logo

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

NCT06361238 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2024-12-20

No results posted yet for this study

Summary

This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.

Conditions

  • Delirium, Postoperative

Interventions

DRUG

Liraglutide injection

Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.

DRUG

Placebo injection

Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Principal Investigators

  • Dongjin Wang, PhD，MD · Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-19
Primary Completion
2027-03-31
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06361238 on ClinicalTrials.gov